By attending Immunogenicty you will be able to:

•Assess the very latest developments within predictive testing for immunogenicity, including characterising families of monoclonal antibodies for accurate prediction

•Understand the challenges and opportunities posed within detection and characterisation of immunogenicity and analyse the latest technologies to enable accurate detection and characterisation

•Ensuring investment into lab automation to cut development timelines

•Implement the latest regulatory changes to ensure compliance

Internationally Renowned Confirmed speakers Include:

•Dr Albert Torri, Senior Director, Assay Development and Sample Analysis, Preclinical Development, Regeneron Pharmaceuticals

•Dr Birgit Reipert, Director, Immunology, Global Preclinical R&D
Baxter

•Dr Huub Schellkens, Department of Innovation Studies, University College London